175 related articles for article (PubMed ID: 22510229)
1. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; França JB; Ferriani RA; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):211-6. PubMed ID: 22510229
[TBL] [Abstract][Full Text] [Related]
2. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
[TBL] [Abstract][Full Text] [Related]
3. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
[TBL] [Abstract][Full Text] [Related]
4. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
[TBL] [Abstract][Full Text] [Related]
5. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
7. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
Yildizhan R; Gokce AI; Yildizhan B; Cim N
Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
[TBL] [Abstract][Full Text] [Related]
9. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
10. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.
Jacob-Ferreira AL; Passos CJ; Jordão AA; Fillion M; Mergler D; Lemire M; Gerlach RF; Barbosa F; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):281-8. PubMed ID: 19594729
[TBL] [Abstract][Full Text] [Related]
11. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome.
Lewandowski KC; Komorowski J; O'Callaghan CJ; Tan BK; Chen J; Prelevic GM; Randeva HS
J Clin Endocrinol Metab; 2006 Mar; 91(3):1173-7. PubMed ID: 16338908
[TBL] [Abstract][Full Text] [Related]
12. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
13. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Ibáñez L; De Zegher F
Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
[TBL] [Abstract][Full Text] [Related]
14. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
15. Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1.
Liu B; Cai LY; Lv HM; Xia L; Zhang YJ; Zhang HX; Guan YM
Gynecol Endocrinol; 2008 May; 24(5):285-8. PubMed ID: 18569034
[TBL] [Abstract][Full Text] [Related]
16. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
18. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
[TBL] [Abstract][Full Text] [Related]
19. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
Guido M; Romualdi D; Campagna G; Ricciardi L; Bompiani A; Lanzone A
Reprod Sci; 2010 Aug; 17(8):767-75. PubMed ID: 20595709
[TBL] [Abstract][Full Text] [Related]
20. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
